PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

To:

ERRATT, Judy, A. Gowling Lafleur Henderson LLP 160 Elgin Street, suite 2600 Ottawa, Ontario K1P 1C3 ETATS-UNIS D'AMERIQUE

RECEIV

MAR 0 8 200

Date of mailing (day/month/year)
23 February 2006 (23.02.2006)

Applicant's or agent's file reference 08898491WO

IMPORTANT NOTICE

International application No. PCT/CA2004/001474

International filing date (day/month/year) 16 August 2004 (16.08.2004) Priority date (day/month/year)
13 August 2003 (13.08.2003)

Applicant

CEAPRO INC. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperati Treaty)

BEST AVAILABLE COPY

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer

Athina Nickitas-Etienne

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 89 95

Form PCT/IB/326 (January 2004)

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 08898491WO	FOR FURTHER A	CTION	See item 4 below		
International application No. PCT/CA2004/001474	International filing date (day/n 16 August 2004 (16.08.200		Priority date (day/month/year) 13 August 2003 (13.08.2003)		
International Patent Classification (See relevant information in Form	8th edition unless older edition inc PCT/ISA/237	licated)			
Applicant CEAPRO INC.					
		<u>-</u>			
	ry report on patentability (Chapter nority under Rule 44 bis.1(a).	I) is issued by the I	International Bureau on behalf of the		
2. This REPORT consists of a	total of 9 sheets, including this co	ver sheet.			
	eference to the written opinion of ary report on patentability (Chapte		arching Authority should be read as a refere	nce	
3. This report contains indicati	ons relating to the following items	::			
Box No. I	Basis of the report				
Box No. II	Priority				
Box No. III	Non-establishment of opin applicability	ion with regard to n	ovelty, inventive step and industrial		
Box No. IV	Lack of unity of invention				
Box No. V	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI	Certain documents cited				
Box No. VII	Certain defects in the inter	national application	ı		
Box No. VIII	Certain observations on the	e international appli	cation		
			ccordance with Rules 44 <i>bis.</i> 3(c) and 93 <i>bis.</i> 1 ore the expiration of 30 months from the pri		
		Date of issuance o 13 February 200			
The International		Authorized officer			
34, chemin des 1211 Geneva 20		/	Athina Nickitas-Etienne		
Facsimile No. +41 22 740 14 35		Telephone No. +4	1 22 338 89 95		

PATENT COUPERATION TREATY REC'D 0 8 DEC 2004 From the INTERNATIONAL SEARCHING AUTHORITY PCT ERRATT, J.A. c/o Gowling Lafleur Henderson LLP WRITTEN OPINION OF THE 2600 - 160 Elgin Street INTERNATIONAL SEARCHING AUTHORITY OTTAWA (Ontario) Canada, K1P 1C3 (PCT Rule 43bis.1) 03 December 2004 (03-12-2004) Date of mailing (date/month/year) FOR FURTHER ACTION Applicant's or agent's file reference See paragraph 2 below 08898491WO Priority date (date/month/year) International filing date (date/month/year)) International application no 13 August 2003 (13-08-2003) 16 August 2004 (16-08-2004) PCT/CA2004/001474 International Patent Classification (IPC) Primary: G01N 33/66 Cross references: G01N 33/02, G01N 33/48, G01N 33/74 Applicant CEAPRO INC. ET AL 1. This opinion contains indications relating to the following items: X Box No. I Basis of the opinion IXI Box No. II **Priority** Non-establishment of opinion with regard to novelty, inventive step and industrial Box No. III [X]applicability Lack of unity of invention Box No. IV [] Reasoned statement under Rule 43bis. I(a)(i) with regard to novelty, inventive step or [X]Box No. V industrial applicability; citations and explanations supporting such statement Certain documents cited Box No. VI []Certain defects in the international application Box No. VII Certain observations on the international application [X] Box No. VIII 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submito the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from th date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/ Authorized officer

Form PCT/ISA/237 (cover sheet) (January 2004)

Commissioner of Patents Canadian Patent Office Box PCT, Ottawa/Gatineau K1A 0C9

Facsimile No. (819) 953-9538

David Boudreau (819) 997-2926

International application No. PCT/CA2004/001474

Box No. I	Basis of this opinion				
1.With reg language v	ard to the language, this opinion has been established on the basis o the international application in the which it was filed, unless otherwise indicated under this item.				
[]	This opinion has been established on the basis of a translation from the original language into the follow language, which is the language of a translation furnished for the purposes of international search (to Rules 12.3 and 23.1(b)).	ving inder			
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessar the claimed invention, this opinion has been established on the basis of:					
a. type of	material				
[·]	a sequence listing				
[]	table(s) related to the sequence listing				
b. format	of material .				
[]	in written format .				
[]	in computer readable from				
c. time of	filing/furnishing .				
[]	contained in the international application as filed.				
[]	filed together with the international application in computer readable form.				
[]	furnished subsequently to this Authority for the purposes of search.				
3.[] In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
4. Additional comments:					

BEST AVAILABLE COPY

International application No. PCT/CA2004/001474

	INTERNATIONAL SEARCHING NO 12			
Box No. II	Priority			
1 [X]	The following document has not yet been furnished:			
	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).			
	[] translation of the earlier application whose priority has been claimed (rule 43bis.1 and 66.7(b)).			
	Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.	S		
2 []	This opinion has been established as if no priority had been claimed due to the fact that the priority claim been found invalid (Rules 43bis.1 and 64.1). Thus for the purpose of this opinion, the international filing indicated above is considered to be the relevant date.	n has g date		
3. Addition	nal observations, if necessary:			
	·			
	-			
	`			
	·			
ļ				
	,			
	·	•		
1	BEST AVAILABLE COPY			

International application No. PCT/CA2004/001474

Box No	. Ш	Non-establishment of opinion with reg	ard to	novelty, inventive step and industrial applicability	
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:					to
[]] 1	the entire international application	•		
[3	X]	claim No. <u>24</u>		·	
be	ecaus	se			
Ĺ	X]	Claim 24 relates to the following subject mate examination (specify):	tter wh	nich does not require an international preliminary	
		under article 17.2 (a)(i) and rule 39(i)	and (arched since it refers to excluded subject mar (v). A method of calculating an average, as sentation of information and a mathematical	lter ·
ί]	the description, claims or drawings (indicate particular elements below) or said claims Nos are so unclear that no meaningful opinion could be formed (specify):			
[]	the claims, or said claims Nos are so ina	dequa	tely supported by the description that no meaningful	
[}	no international search report has been estab	lished	for said claims Nos	
[[] the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Ar of the Administrative Instructions in that:			loes not comply with the standard provided for in Ann	ex C
ti	he w	ritten form	[]	has not been furnished	
			[]	does not comply with the standard	
ti	he c	omputer readable form	[]	has not been furnished	
			[]	does not comply with the standard	
[]	the tables related to the nucleotide and/or am not comply with the technical requirements p	iino ac provid	id sequence listing, if in computer readable form only ed for in Annex C-bis of the Administrative Instruction	, do ns.
[]	See Supplemental Box for further details.			

Form PCT/ISA/237 (Box No. III) (January 2004)

International application No. PCT/CA2004/001474

Box No	o. IV	Lack of unity of invention	
1	[]	In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has:	
		[] paid additional fees	
		[] paid additional fees under protest	
		[] not paid additional fees	
2	[]	This Authority found that the requirement of unity of invention is not complied with and chose not to the applicant to pay additional fees.	
3	This	Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 1	3.3 is
	[]	complied with	
	[]	not complied with for the following reasons:	
		•	
		<u>.</u>	
1			
		•	
	•		
4	Cor	asequently, this opinion has been established in respect of the following parts of the international applic	ation:
	[]	all parts	
	. []	the ments relating to eleting Nos	
		BEST AVAILABLE COPY	

International application No. PCT/CA2004/001474

NO

ox No. V reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
Statement			-
A. Novelty (N)	Claims	1-23	YES
	Claims	, NA	NO
B. Inventive step (IS)	Claims	1-23	YES
	Claims	NA	NO
C. Industrial applicability (IA)	Claims	1-14, and 21-22	YES

Claims

Claims

15-20, and 23

2. Citations and explanations:

C. Industrial applicability (IA)

D1: WO9702050

D2; Jenkins et al. (2002). Eur. J. Clin. Nutr. 56(7): 622-628.

The subject matter of the alleged invention differs from the closest prior art (D1), in that the diagnostic test meal of the present invention contains a low soluble fibre content (less than 0.5 wt. %), whereas D1's diagnostic test meal contains about 1.5 wt. % of soluble fibre. Therefore, the claims on file comply with article 33.2 of the Patent Cooperation Treaty (PCT).

B. Inventive step

Claim 1, which is novel, is also non-obvious. The closest prior art (D2) relating with soluble fibre and glucose absorption, would not lead a skilled person in the art to design a diagnostic test meal containing less than 0.5 w.t % of soluble fibre. Therefore, the claims on file comply with article 33.3 of the Patent Cooperation Treaty (PCT).

C. Industrial applicability

Claims 15-20 and 23 do not have an industrial applicability as defined under article 33.4 of the Patent Cooperation Treaty (PCT). Although both claims specified utility by indicating how useful the methods may diagnose a given disorder, they both failed to indicate how the diagnosing step would be performed. The dependent claims 16-20, which depend on claim 15, do not add an industrial applicability.

International application No. PCT/CA2004/001474

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

Claim defects

Claim 1 does not comply with article 6 of the *Patent Cooperation Treaty (PCT)*. An independent claim should clearly specify all the essential features needed to define the invention. It appears that the following feature (below), indicated in the description, would be essential to the performance of the alleged invention. This feature should be incorporated in the above claim.

"[The diagnostic test meal provides] a selected quantity of glycemic carbohydrate ..."

(page 19, lines 1-4).

The claims on file lack clarity (article 6 of the Patent Cooperation Treaty) and are inconsistent (rule

10.2 of the Regulations under the PCT).

From the wording of the claims 4, 8 and 9, it is understood that mono- and disaccharides would not represent glycemic carbohydrates, since the prefix "glycemic" is not utilized. However, from the reading of the description, the expression "glycemic carbohydrate" is defined as glucose or a complex carbohydrate, which can be metabolized or reduced to glucose. Both glucose (monosaccharide) and sucrose (disaccharide) contain glucose, and could therefore be associated to the expression "glycemic carbohydrate". Hence, the expression "glycemic carbohydrate" is unclear.

Claims 1 and 14 refer to the term "polysaccharide", which is inconsistent with claims 4 and

11, which refer to the expression "glycemic polysaccharide".

Claims 15 and 23 do not comply with article 6 of the *Patent Cooperation Treaty (PCT)*. The above claims are incomplete and are silent on essential features needed to define the invention.

Claim 15 refers to a method of diagnosing a disorder of carbohydrate metabolism in a vertebrate subject. Claim 15 is incomplete being silent on how the diagnosing step is performed and fails to provide at which time the blood sample is taken for the glucose concentration measurement.

• Claim 23 refers to a method of diabetes self-diagnosis and self-monitoring in a vertebrate subject. Claim 23 is incomplete being silent on the comparison step (comparing the obtain glucose concentration with a reference value), and how the diagnosing and monitoring steps are performed. Claim 23 also fails to provide when the blood sample is taken after ingestion, for glucose concentration measurement.

Claims 11 and 15 do not comply with article 6 of the *Patent Cooperation Treaty (PCT)*. The following expressions have no antecedent, which render the scope of the claims unclear: "glycemic polysaccharide" (claim 11, lines 7-8), when dependent on claims 1-3; "biological sample" (claim 15, line 29), when dependent on claims 1-14.

Note to the applicant:

The expression "biological sample" (claim 16, line 33) have already been defined in claim 15, and should therefore be referred to using a definite article to avoid double inclusion.

BEST AVAILABLE COPY

International application No. PCT/CA2004/001474

Box No. VIII	Certain observations of	n the international	application
--------------	-------------------------	---------------------	-------------

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Description defects

The description encompasses a discrepancy and does not comply with article 5 of the *Patent Cooperation Treaty (PCT)*. The reference "Haber et al." (page 4, line 32) is not clearly identified in such a manner that the document could be easily retrieved.

BEST AVAILABLE COPY